| scholarly article | Q13442814 |
| P2093 | author name string | Zhimin Huang | |
| Bin Yao | |||
| Wen Xu | |||
| Guoliang Hu | |||
| Yanbing Li | |||
| Zhihong Liao | |||
| Xiahua Chen | |||
| JianPing Weng | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell function | Q95674809 |
| patient | Q181600 | ||
| P304 | page(s) | 2597-2602 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | |
| P478 | volume | 27 |
| Q80085802 | A public health approach to the diabetes epidemic: New York City's diabetes registry |
| Q35879135 | Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment |
| Q42933616 | Barriers to achieving glycemic targets: who omits insulin and why? |
| Q36906173 | Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy |
| Q36453667 | Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections |
| Q38503820 | Case Study: Remission of Type 2 Diabetes After Outpatient Basal Insulin Therapy |
| Q51301686 | Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes. |
| Q38115799 | Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes |
| Q41705110 | Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q81858328 | Current literature in diabetes |
| Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
| Q42446656 | Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes |
| Q34729059 | Diabetes management: optimizing roles for nurses in insulin initiation |
| Q35027017 | Diet is critical for prolonged glycemic control after short-term insulin treatment in high-fat diet-induced type 2 diabetic male mice |
| Q37102846 | Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes? |
| Q37509313 | Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated |
| Q51245935 | EADSG Guidelines: Insulin Therapy in Diabetes. |
| Q26767164 | Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials |
| Q35853273 | Early basal insulin therapy decreases new-onset diabetes after renal transplantation. |
| Q37624279 | Early insulin treatment in type 2 diabetes: what are the pros? |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q40187492 | Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial |
| Q36843216 | Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients |
| Q46576386 | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. |
| Q42477142 | Effect of short‐term intensive insulin therapy on quality of life in type 2 diabetes |
| Q36310386 | Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study |
| Q42493971 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes |
| Q31144148 | Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data |
| Q37384190 | Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. |
| Q86582910 | Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes |
| Q51367108 | Effects of the modified linggui zhugan decoction (see text) combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics. |
| Q34319707 | Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study |
| Q48031376 | Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period |
| Q58700185 | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial |
| Q35214425 | Emerging role of insulin with incretin therapies for management of type 2 diabetes |
| Q37639310 | Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial |
| Q58613934 | Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care |
| Q64884015 | Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes. |
| Q37733563 | Genetics of new-onset diabetes after transplantation |
| Q37921903 | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? |
| Q90899756 | Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study) |
| Q57822731 | Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control - Continuous Glucose Monitoring is the Solution |
| Q90152701 | Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q42140404 | Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission |
| Q42435709 | Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion |
| Q44598061 | Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control |
| Q36194286 | Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy |
| Q51287734 | Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. |
| Q34103753 | Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats |
| Q38065105 | Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia |
| Q42477903 | Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin |
| Q42756047 | Insulin concerns and promises |
| Q43098208 | Insulin detemir: A historical perspective on a modern basal insulin analogue |
| Q81157739 | Insulin may have a role to play in protecting beta cells from deterioration in diabetes |
| Q34585855 | Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding |
| Q54353931 | Insulin therapy improves islet functions by restoring pancreatic vasculature in high-fat diet-fed streptozotocin-diabetic rats. |
| Q37728180 | Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice |
| Q27024597 | Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial |
| Q37364945 | Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? |
| Q44004103 | Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial. |
| Q53475411 | Intensive insulin therapy in newly diagnosed type 2 diabetes. |
| Q34586302 | Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial |
| Q37281205 | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
| Q38862406 | Long-term blood glucose monitoring with implanted telemetry device in conscious and stress-free cynomolgus monkeys |
| Q48199510 | Lower mean blood glucose during short-term intensive insulin therapy is associated with long-term glycemic remission in patients with newly diagnosed type 2 diabetes: Evidence-based recommendations for standardization. |
| Q58717025 | Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients |
| Q37886705 | Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team |
| Q37102861 | Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes |
| Q37133799 | Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study |
| Q37653764 | Metabolic Stress and Compromised Identity of Pancreatic Beta Cells. |
| Q55447873 | Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. |
| Q42918366 | No need for the needle (at first). |
| Q35645893 | Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q50921668 | Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus. |
| Q37404011 | Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes |
| Q38784851 | Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in db/db Mice |
| Q89475403 | Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site |
| Q90025604 | Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes |
| Q39468025 | Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q42718198 | Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises |
| Q91618221 | Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db/db Mice |
| Q55288083 | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. |
| Q37192464 | Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus |
| Q38038662 | Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q42511731 | Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. |
| Q38195430 | Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis |
| Q35123342 | Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission |
| Q37412792 | Standards of care for type 2 diabetes in China. |
| Q54985686 | Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. |
| Q36030232 | Syntaxin 4 Overexpression Ameliorates Effects of Aging and High-Fat Diet on Glucose Control and Extends Lifespan |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q34102119 | The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients |
| Q51346853 | The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes. |
| Q44685753 | The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes |
| Q38442291 | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. |
| Q84355336 | The influence of insulin pump treatment on metabolic syndrome parameters in type 2 diabetes mellitus |
| Q38836724 | The role of insulin pump therapy for type 2 diabetes mellitus |
| Q34127409 | The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus |
| Q37308148 | Treatment of diabetes mellitus using an external insulin pump: the state of the art. |
| Q26859746 | Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States |
| Q61795976 | Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review |
| Q47099550 | Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. |
Search more.